The UK Competition and Markets Authority has extended the reference period for its review of the proposed Getty Images‑Shutterstock merger to June 14 2026, giving regulators additional time to evaluate competition concerns, particularly in the UK editorial content market.
The merger, valued at approximately $3.7 billion, is expected to deliver $150‑$200 million in annual cost synergies by year three. While the U.S. Department of Justice cleared the deal without conditions, the CMA has referred the transaction to a Phase 2 investigation and has identified provisional competition concerns in the UK editorial market, prompting the extension.
The delay could postpone the synergies and market‑share gains that Shutterstock’s management has highlighted as critical to its growth strategy. CEOs Craig Peters of Getty Images and Paul Hennessy of Shutterstock have reiterated their commitment to securing regulatory approval, noting that the merger will strengthen their financial foundations and enable investment in future growth, including AI‑driven capabilities.
Financially, Shutterstock reported Q4 2025 earnings that missed consensus estimates, with revenue falling 12% to $220.22 million. Getty Images is expected to report Q4 2025 results on March 16 2026, with analysts forecasting EPS of $0.03 and revenue of $246.17 million. The merger is positioned as a strategic response to the rising threat of AI‑generated content in the stock‑content market.
Investors are closely watching the CMA’s outcome, as the UK regulatory focus on editorial content introduces a headwind that could delay the merger’s completion. The DOJ’s unconditional clearance remains a positive signal, but the extended review period underscores the importance of regulatory approval for the deal’s long‑term value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.